Epstein–Barr virus renders the infected natural killer cell line, NKL resistant to doxorubicin-induced apoptosis
2008
EBV Makes NK Cells Resistant to Doxorubicin
publication
Evidence: moderate
Author Information
Author(s): Isobe Y, Sugimoto K, Matsuura I, Takada K, Oshimi K
Primary Institution: Juntendo University School of Medicine
Hypothesis
Does Epstein–Barr virus (EBV) infection confer resistance to doxorubicin-induced apoptosis in natural killer (NK) cells?
Conclusion
EBV infection renders NKL cells resistant to doxorubicin-induced apoptosis through NF-κB activation and increased levels of antiapoptotic proteins.
Supporting Evidence
- EBV-infected NKL sublines showed no growth advantage compared to EBV-negative NKL.
- After doxorubicin treatment, less than 14% of EBV-infected cells died compared to approximately 60% of NKL cells.
- The expression levels of antiapoptotic proteins like Bcl-XL and FLIPL/S were maintained in EBV-infected cells after treatment.
Takeaway
When NK cells get infected by EBV, they become tough and don't die easily when treated with a cancer drug called doxorubicin.
Methodology
The study involved establishing EBV-infected NKL sublines and assessing their resistance to doxorubicin through various assays.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website